SCHEMBL683499

SCHEMBL683499

CC(=O)c1c(C)nn2cccc(Br)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.38
ALDH1A1 P00352 4/20 0.37
KMT2A Q03164 3/20 0.37
HSD17B10 Q99714 2/20 0.37
TDP1 Q9NUW8 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
MAP4K4 O95819 1/20 0.34
ABL1 P00519 1/20 0.34
MAPK8 P45983 1/20 0.34
CSNK1A1 P48729 1/20 0.34
CDK7 P50613 1/20 0.34
TYRO3 Q06418 1/20 0.34
LRRK2 Q5S007 1/20 0.34
AURKB Q96GD4 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
DYRK1B Q9Y463 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265389 0.89 POLB (0.44) POLBKMT2ATDP1L3MBTL1CYP1A2
SCHEMBL7373297 0.84 POLB (0.39) POLBALDH1A1KMT2AHSD17B10TDP1
SCHEMBL683558 0.83 THRB (0.44) POLBALDH1A1KMT2AHSD17B10TDP1
SCHEMBL682711 0.79 GAA (0.40) ALDH1A1KMT2AHSD17B10L3MBTL1TP53
SCHEMBL683860 0.78 ALDH1A1 (0.37) POLBALDH1A1KMT2AHSD17B10TDP1
SCHEMBL5848990 0.72 ALDH1A1 (0.51) POLBALDH1A1KMT2AHSD17B10TDP1
SCHEMBL684214 0.71 PDE4B (0.60) ALDH1A1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL17867572 0.70 NTRK1 (0.39) POLBALDH1A1KMT2ATDP1L3MBTL1
SCHEMBL20669696 0.68 PIK3CG (0.51) ALDH1A1KMT2AHSD17B10L3MBTL1LMNA
SCHEMBL17867588 0.67 KDM4E (0.46) POLBALDH1A1KMT2ATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF POLB 1723/4885ALDH1A1 1565/4885KMT2A 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.